Ajooni Biotech Limited (AJOONI) — Multibagger Analysis

1. Catalyst & Ramp-Aware Impact Analysis

Ajooni Biotech's AGM approval of a preferential equity issue marks the execution step of its strategic expansion plan. - TTM Revenue Base: ₹182.38 Cr (FY26). - Capacity Expansion & Mix Shift: The company is deploying a new ₹16.5 Cr manufacturing unit dedicated to higher-margin (9-10%) feed supplements vs traditional compound cattle feed. - Dilution vs Growth: While the equity base will expand via preferential issuance, funds will support working capital and capacity utilization. - Ramp Math: - Year 1 Revenue Uplift: ~15% (reaching ~₹210 Cr) as new capacity ramps up. - Steady-State Uplift: ~30% (reaching ~₹235-240 Cr) over 24 months. - Margin Impact: Expanding OPM from 3.4% to ~4.8% on higher supplement share yields steady-state PAT of ~₹7.5-8.5 Cr (vs ₹4.3 Cr TTM). - EPS Impact: Accounting for estimated 15-20% share dilution, net steady-state EPS growth is estimated at ~20-25%.

2. Industry Dynamics & Capital Intensity

• Capital Intensity: Medium. Facility capex is modest (₹16.5 Cr), but working capital requirements are ongoing given agricultural procurement cycles.
• Industry Growth: Indian animal feed/nutrition industry is growing at 8-10% CAGR driven by dairy yield enhancement initiatives.
• Execution Difficulty: Moderate. Operating risk lies primarily in raw material price volatility (maize, mustard oil cake) which cannot easily be passed through due to fragmented competition.

3. Fundamental Quality & Governance Evaluation

• ROCE: Low at 6.0%, failing the standard quality gate threshold (>15%).
• Margins: Thin OPM of 3.4% and NPM of 2.36% leave minimal buffer against operational shocks.
• Promoter Holding: 26.89% is significantly below the 35% benchmark, triggering a hard cap on verdict confidence.
• Balance Sheet: D/E is clean at 0.20x with net worth at ₹91 Cr.

4. Scenario Analysis & Valuation Headroom

• Current Valuation: Price ₹4.0, Market Cap ₹66 Cr, Trailing P/E 15.2x (vs peer median 20.9x).
• Base Case (+20%): Revenue reaches ₹215 Cr with OPM at 4.5%; PAT ₹6.5 Cr. Target P/E 15x gives market cap ~₹80 Cr.
• Bull Case (+50%): Revenue reaches ₹240 Cr with supplement mix lifting OPM to 5.5%; PAT ₹9.5 Cr. Re-rating to 18x P/E yields market cap ~₹100 Cr.
• Bear Case (-30%): Raw material inflation depresses OPM to 2.5%; dilution hurts EPS without margin expansion. Market cap contracts to ~₹46 Cr.

5. Verdict Rationale & Mandatory Caps

Under strict research guardrails, Promoter Holding < 35% (26.89%) caps the verdict at POSSIBLE and confidence at <= 0.50. While top-line growth is strong (59% in FY26), thin margins and equity dilution prevent a stronger rating until margin expansion materializes.

1. Ramp-Aware Impact Math

Ajooni Biotech has secured its largest-ever order of ’47.52 Cr, which represents approximately 37.7% of its TTM revenue of ’126 Cr. Unlike long-gestation infrastructure projects, cattle feed orders are typically executed within a 12-month timeframe. Therefore, we model a Year-1 revenue uplift of 37.7% (’47.52 Cr) directly from this order.

Simultaneously, the company has commissioned its new plant in Khanna, Punjab, tripling its annual production capacity to 1,80,000 MT. The impact of this capacity expansion is already visible in the Q3 FY26 numbers (reported in prior filings), where revenue surged to ’58.75 Cr (annualizing to over ’230 Cr).

Earnings Projection: - Current TTM: Revenue ’126 Cr, PAT ’4 Cr, EPS ’0.23 (on ~17.25 Cr shares). - Steady-State (12-24 months): Assuming the expanded capacity operates at ~60% utilization, annual revenue can reach ’200 Cr. - Margin Expansion: With the strategic shift to high-margin feed supplements (9-10% margins), we expect overall OPM to improve from 3.3% to 5.0%, yielding a net profit margin of ~3.5%. - Projected PAT: ’200 Cr * 3.5% = ’7.0 Cr. - Projected EPS: ’7.0 Cr / 17.25 Cr shares = ’0.41, representing a 78% increase over current TTM EPS.

2. Industry Capital Intensity & CAGR

The animal feed and processing industry in India has medium capital intensity. While setting up manufacturing plants requires moderate capex (’16.5 Cr for Ajooni's new plant), the primary challenge is working capital management due to seasonal raw material procurement. The industry is structurally growing at a CAGR of ~10%, driven by increasing professionalization of dairy farming and a shift toward compound feed and nutritional supplements to improve livestock yields.

3. Multibagger Quality Assessment

• Growth & Acceleration: Revenue and PAT are showing strong acceleration. Q3 FY26 net profit jumped 125% YoY to ’1.65 Cr, driven by the commencement of the Khanna facility.
• Margins & ROCE: Trailing ROCE is weak at 7.0%, and OPM is low at 3.3%. This is a key risk, though the shift to specialized feed supplements offers a credible path to margin expansion.
• Balance Sheet: Excellent debt profile with a D/E of 0.02 and net worth strengthened to ’88 Cr via a ’40 Cr rights issue in FY25.
• Promoter Holding: At 26.89%, the promoter holding is extremely low, which is a major structural risk and limits our ultimate conviction.

4. Scenario Analysis (12-24 Months)

• Base Case (35% Upside): Revenue reaches ’200 Cr, OPM improves to 4.5%, PAT reaches ’6.5 Cr. Applying a conservative P/E of 18x (reflecting low promoter holding) yields a target price of ~’6.8.
• Bull Case (75% Upside): Successful merger with Healthy Biosciences, rapid ramp-up of capacity to 80% utilization, revenue reaches ’240 Cr, OPM expands to 5.5%, PAT reaches ’9.2 Cr. EPS rises to ’0.53. At a 17x P/E, target price is ’9.0.
• Bear Case (-25% Downside): Raw material price spikes (maize/mustard) compress margins back to 3%, or working capital stress limits capacity utilization. PAT remains stagnant at ’4 Cr, and the stock de-rates to 15x P/E, leading to a price of ’3.8.

5. Verdict Rationale

While the operational turnaround is highly visible (tripled capacity, record order, and surging Q3 FY26 earnings), the catalyst is already priced in as the order was first disclosed on Feb 6, 2026. Furthermore, the extremely low promoter holding of 26.89% acts as a hard governance cap under our rules, limiting the verdict to POSSIBLE and confidence to 0.50.